Literature DB >> 22190050

The Tumor-Promoting Flow of Cells Into, Within and Out of the Tumor Site: Regulation by the Inflammatory Axis of TNFα and Chemokines.

Adit Ben-Baruch1.   

Abstract

Tumors are dynamic organs, in which active processes of cell motility affect disease course by regulating the composition of cells at the tumor site. While sub-populations of tumor-promoting leukocytes are recruited inward and endothelial cell migration stands in the basis of vascular branching throughout the tumor, cancer cells make their way out of the primary site towards specific metastatic sites. This review describes the independent and cross-regulatory roles of inflammatory chemokines and of the inflammatory cytokine tumor necrosis factor α (TNFα) in determining cell motility processes that eventually have profound effects on tumor growth and metastasis. First, the effects of inflammatory chemokines such as CCL2 (MCP-1), CCL5 (RANTES) and CXCL8 (IL-8) are described, regulating the inward flow of leukocyte sub-populations with pro-tumoral activities, such as tumor-associated macrophages (TAM), myeloid-derived suppressor cells (MDSC), tumor-associated neutrophils (TAN), Th17 cells and Tregs. Then, the ability of inflammatory chemokines to induce endothelial cell migration, sprouting and tube formation is discussed, with its implications on tumor angiogenesis. This part is followed by an in depth description of the manners by which TNFα potentiates the above activities of the inflammatory chemokines, alongside with its ability to directly induce migratory processes in the tumor cells thus promoting metastasis. Note worthy is the ability of TNFα to induce in the tumor cells the important process of epithelial-to-mesenchymal transition (EMT). Emphasis is given to the ability of TNFα to establish an inflammatory network with the chemokines, and in parallel to form a cell re-modeling network together with transforming growth factor β (TGFβ). The review concludes by discussing the implications of such networks on disease course, and on the future design of therapeutic measures in cancer.

Entities:  

Year:  2011        PMID: 22190050      PMCID: PMC3399063          DOI: 10.1007/s12307-011-0094-3

Source DB:  PubMed          Journal:  Cancer Microenviron        ISSN: 1875-2284


  171 in total

1.  Gene expression of the invasive phenotype of TNF-alpha-treated MCF-7 cells.

Authors:  Yongmei Yin; Xiaofeng Chen; Yongqian Shu
Journal:  Biomed Pharmacother       Date:  2009-06-13       Impact factor: 6.529

2.  Genome-wide analysis of aberrant methylation in human breast cancer cells using methyl-DNA immunoprecipitation combined with high-throughput sequencing.

Authors:  Yoshinao Ruike; Yukako Imanaka; Fumiaki Sato; Kazuharu Shimizu; Gozoh Tsujimoto
Journal:  BMC Genomics       Date:  2010-02-25       Impact factor: 3.969

3.  Human neutrophils facilitate tumor cell transendothelial migration.

Authors:  Q D Wu; J H Wang; C Condron; D Bouchier-Hayes; H P Redmond
Journal:  Am J Physiol Cell Physiol       Date:  2001-04       Impact factor: 4.249

4.  Role of tumor necrosis factor-alpha and its receptors in human benign breast lesions and tumors (in situ and infiltrative).

Authors:  Ignacio García-Tuñón; Mónica Ricote; Antonio Ruiz; Benito Fraile; Ricardo Paniagua; Mar Royuela
Journal:  Cancer Sci       Date:  2006-10       Impact factor: 6.716

5.  Tumor necrosis factor-alpha enhances both epithelial-mesenchymal transition and cell contraction induced in A549 human alveolar epithelial cells by transforming growth factor-beta1.

Authors:  Yasuhiro Yamauchi; Tadashi Kohyama; Hajime Takizawa; Sumiko Kamitani; Masashi Desaki; Kazutaka Takami; Shin Kawasaki; Jun Kato; Takahide Nagase
Journal:  Exp Lung Res       Date:  2010-02       Impact factor: 2.459

6.  Involvement of a novel chemokine decoy receptor CCX-CKR in breast cancer growth, metastasis and patient survival.

Authors:  Lan-Yun Feng; Zhou-Luo Ou; Feng-Ying Wu; Zhen-Zhou Shen; Zhi-Ming Shao
Journal:  Clin Cancer Res       Date:  2009-04-21       Impact factor: 12.531

7.  A phase II study of etanercept (Enbrel), a tumor necrosis factor alpha inhibitor in patients with metastatic breast cancer.

Authors:  Srinivasan Madhusudan; Martin Foster; Sethupathi R Muthuramalingam; Jeremy P Braybrooke; Susan Wilner; Kulwinder Kaur; Cheng Han; Susan Hoare; Frances Balkwill; Denis C Talbot; Trivadi S Ganesan; Adrian L Harris
Journal:  Clin Cancer Res       Date:  2004-10-01       Impact factor: 12.531

8.  Effect of pro-inflammatory cytokine stimulation on human breast cancer: implications of chemokine receptor expression in cancer metastasis.

Authors:  Julio E Valdivia-Silva; Janusz Franco-Barraza; Ana Luisa Esparza Silva; Gisela Du Pont; Gloria Soldevila; Isaura Meza; Eduardo A García-Zepeda
Journal:  Cancer Lett       Date:  2009-05-05       Impact factor: 8.679

9.  Luminal and basal-like breast cancer cells show increased migration induced by hypoxia, mediated by an autocrine mechanism.

Authors:  Melanie J Voss; Mischa F Möller; Desmond G Powe; Bernd Niggemann; Kurt S Zänker; Frank Entschladen
Journal:  BMC Cancer       Date:  2011-05-02       Impact factor: 4.430

10.  The actin filament cross-linker L-plastin confers resistance to TNF-alpha in MCF-7 breast cancer cells in a phosphorylation-dependent manner.

Authors:  Bassam Janji; Laurent Vallar; Ziad Al Tanoury; François Bernardin; Guillaume Vetter; Elisabeth Schaffner-Reckinger; Guy Berchem; Evelyne Friederich; Salem Chouaib
Journal:  J Cell Mol Med       Date:  2009-10-03       Impact factor: 5.310

View more
  34 in total

1.  Minimal changes in the systemic immune response after nephrectomy of localized renal masses.

Authors:  Gal Wald; Kerri T Barnes; Megan T Bing; Timothy P Kresowik; Ann Tomanek-Chalkley; Tamara A Kucaba; Thomas S Griffith; James A Brown; Lyse A Norian
Journal:  Urol Oncol       Date:  2014-04-24       Impact factor: 3.498

2.  Inflammatory factors of the tumor microenvironment induce plasticity in nontransformed breast epithelial cells: EMT, invasion, and collapse of normally organized breast textures.

Authors:  Tal Leibovich-Rivkin; Yulia Liubomirski; Biana Bernstein; Tsipi Meshel; Adit Ben-Baruch
Journal:  Neoplasia       Date:  2013-12       Impact factor: 5.715

Review 3.  Recent Advances Targeting CCR5 for Cancer and Its Role in Immuno-Oncology.

Authors:  Xuanmao Jiao; Omar Nawab; Tejal Patel; Andrew V Kossenkov; Niels Halama; Dirk Jaeger; Richard G Pestell
Journal:  Cancer Res       Date:  2019-07-10       Impact factor: 12.701

4.  Increased circulating myeloid-derived suppressor cells correlate with cancer stages, interleukin-8 and -6 in prostate cancer.

Authors:  Ning Chi; Zhaohui Tan; Kewei Ma; Lidao Bao; Zhizhong Yun
Journal:  Int J Clin Exp Med       Date:  2014-10-15

Review 5.  The Breast Cancer Protooncogenes HER2, BRCA1 and BRCA2 and Their Regulation by the iNOS/NOS2 Axis.

Authors:  Katie Lin; Stavroula Baritaki; Silvia Vivarelli; Luca Falzone; Aurora Scalisi; Massimo Libra; Benjamin Bonavida
Journal:  Antioxidants (Basel)       Date:  2022-06-17

6.  The synthetic parasite-derived peptide GK1 increases survival in a preclinical mouse melanoma model.

Authors:  Armando Pérez-Torres; Jesús Vera-Aguilera; Juan Carlos Hernaiz-Leonardo; Eduardo Moreno-Aguilera; Diego Monteverde-Suarez; Carlos Vera-Aguilera; Daniel Estrada-Bárcenas
Journal:  Cancer Biother Radiopharm       Date:  2013-07-10       Impact factor: 3.099

Review 7.  The G protein coupled receptor CCR5 in cancer.

Authors:  Chandan Upadhyaya; Xuanmao Jiao; Anthony Ashton; Kishan Patel; Andrew V Kossenkov; Richard G Pestell
Journal:  Adv Cancer Res       Date:  2020-01-10       Impact factor: 6.242

8.  CXCL5/CXCL8 is a promising potential prognostic and tumor microenvironment-related cluster in hepatocellular carcinoma.

Authors:  Jun Zhu; Yifan Zhou; Liang Wang; Jun Hao; Rui Chen; Lei Liu; Jipeng Li
Journal:  J Gastrointest Oncol       Date:  2020-12

Review 9.  Pro- and Antiangiogenic Factors in Gliomas: Implications for Novel Therapeutic Possibilities.

Authors:  Magdalena Groblewska; Barbara Mroczko
Journal:  Int J Mol Sci       Date:  2021-06-07       Impact factor: 5.923

10.  Neem leaf glycoprotein activates CD8(+) T cells to promote therapeutic anti-tumor immunity inhibiting the growth of mouse sarcoma.

Authors:  Atanu Mallick; Subhasis Barik; Kuntal Kanti Goswami; Saptak Banerjee; Sarbari Ghosh; Koustav Sarkar; Anamika Bose; Rathindranath Baral
Journal:  PLoS One       Date:  2013-01-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.